Specifically, inspired by earlier work on IL2-enhanced ACT for cancer therapy (86–88), we showed that recombinant IL2 administered in 12-hour intervals resulted in enhanced antiviral protection equivalent to daily doublings of the effector cell population (23). Here, IL2 is linked to cancer.